Sign In
Buy SCPH
$5.67
+0 (+0%)
At Close: Jan 06, 2026
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
06:20pm, Tuesday, 14'th May 2024
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.30 per share a year ago.
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
04:01pm, Tuesday, 14'th May 2024
Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack
scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
04:05pm, Monday, 13'th May 2024
BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
04:05pm, Tuesday, 07'th May 2024
BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2
scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript
07:32pm, Wednesday, 13'th Mar 2024
scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
04:01pm, Wednesday, 13'th Mar 2024
Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
04:01pm, Wednesday, 06'th Mar 2024
BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to opti
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
04:01pm, Wednesday, 28'th Feb 2024
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
04:05pm, Thursday, 04'th Jan 2024
Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million
scPharmaceuticals Q3 Earnings: Cruising Toward Success
02:57am, Sunday, 12'th Nov 2023
Q3 earnings report shows positive performance, with Furoscix net sales exceeding consensus estimates. scPharmaceuticals' progress in securing payer coverage and IDN agreements is driving confidence in
Short squeeze alert for November 9th: 2 stocks that could surge
11:03am, Thursday, 09'th Nov 2023
Among various strategies and methods used in stock trading, shorting is a daring one. Seen as a high-risk approach, it involves borrowing and selling stocks, betting on their price decline.
scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript
09:58pm, Wednesday, 08'th Nov 2023
scPharmaceuticals Inc (NASDAQ:SCPH ) Q3 2023 Earnings Call Transcript November 8, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parson
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
04:01pm, Wednesday, 08'th Nov 2023
Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wedn
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
08:00am, Tuesday, 31'st Oct 2023
BURLINGTON, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
